Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Tria completes $12 million funding round with participation from Aptos and others

Tria completes $12 million funding round with participation from Aptos and others

BlockBeatsBlockBeats2025/10/15 03:13
Show original

BlockBeats News, October 15, according to The Block, self-custody bank Tria has completed a $12 million pre-seed and strategic funding round, aiming to build a new global self-custody bank for both humans and AI agents. Participants in this funding round include P2 Ventures, Aptos, the Tria community, as well as executives from Polygon, Ethereum Foundation, Wintermute, Sentient, 0G, Concrete, Eigen, and other companies.


Tria is dedicated to solving the practical challenges of cryptocurrency usage, allowing users to spend, trade, and earn from a single self-custody balance without worrying about gas fees, cross-chain bridges, or mnemonic phrases. Its Visa card supports use in over 150 countries and is compatible with more than 1,000 tokens.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Profit surges 7-fold, revenue breaks 100 trillions for the first time: SK hynix (SKHY.US) responds to AI bubble concerns with record-breaking quarterly report

SK Hynix reported an operating profit of 83.3 trillion won for the third quarter, surpassing expectations, and announced shareholder returns of approximately 100 trillion won within the year.

智通财经•2026/10/28 00:37
Profit surges 7-fold, revenue breaks 100 trillions for the first time: SK hynix (SKHY.US) responds to AI bubble concerns with record-breaking quarterly report

AstraZeneca (AZN.US) CEO hints at entry into cancer vaccines: years of experience with mRNA technology and more updates expected in the coming months

AstraZeneca is considering developing a cancer vaccine, with the CEO stating that the company has already accumulated experience in mRNA technology. Personalized vaccines have reduced the recurrence rate of melanoma by 42%, but cost and production capacity remain obstacles to broader adoption.

智通财经•2026/10/28 00:17
AstraZeneca (AZN.US) CEO hints at entry into cancer vaccines: years of experience with mRNA technology and more updates expected in the coming months